Articles

AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL

Classical Hodgkin lymphoma (cHL) and anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) are B and T cell lymphomas respectively, which express the tumour necrosis factor receptor s...

Authors: Zuoqiao Wu, Mary Nicoll and Robert J. Ingham

Targeting phosphoglycerate dehydrogenase in multiple myeloma

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are requi...

Authors: Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas and Magne Børset

The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers

The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicti...

Authors: Qiao-Xuan Wang, Chun-Hua Qu, Yuan-Hong Gao, Pei-Rong Ding, Jing-Ping Yun, Dan Xie and Mu-Yan Cai

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1...

Authors: Sakshi Jasra, Mohammed Kazemi, Nishi Shah, Jiahao Chen, Karen Fehn, Yanhua Wang, Ioannis Mantzaris, Noah Kornblum, Alejandro Sica, LizaMarie Bachier, Mendel Goldfinger, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Aditi Shastri and Amit Verma

Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country

Authors: Ana Muntañola, Guillermo Villacampa, José Ángel Hernández-Rivas, Rosalía Alonso, Fátima Mirás, Santiago Osorio, Mónica Baile, Patricia Baltasar, Javier López Jiménez, Ines Hernandez-Rodriguez, Susana Valenciano, Ana Alfayate, Eva Gimeno, Abelardo Bárez, Ana C. Oliveira, Rosalía Riaza…

CD44 as a tumor biomarker and therapeutic target

CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberra...

Authors: Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu and Aiguo Liu

Applications of gut microbiota in patients with hematopoietic stem-cell transplantation

Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system. The dysbiosis, a disruption of...

Authors: Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan and Zhongxing Jiang

Engineering better chimeric antigen receptor T cells

CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of ...

Authors: Hao Zhang, Pu Zhao and He Huang

Recent updates for antibody therapy for acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy arising from precursors of the lymphoid lineage. Conventional cytotoxic chemotherapies have resulted in high cure rates of up to 90% in pediatric ...

Authors: Le Li and Ying Wang

Complex roles of cAMP–PKA–CREB signaling in cancer

Cyclic adenosine monophosphate (cAMP) is the first discovered second messenger, which plays pivotal roles in cell signaling, and regulates many physiological and pathological processes. cAMP can regulate the t...

Authors: Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang and Hui Hua

Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-A...

Authors: Ruyue Zheng, Menglin Li, Shujuan Wang and Yanfang Liu

Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma

Peripheral T-cell lymphomas (PTCLs) are biologically and clinically heterogeneous diseases almost all of which are associated with poor outcomes. Recent advances in gene expression profiling that helps in diag...

Authors: Caiqin Xie, Xian Li, Hui Zeng and Wenbin Qian

Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study

Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to ...

Authors: Liqing Ning, Chuanyu Hu, Pingfan Lu, Yimei Que, Xiaojian Zhu and Dengju Li

Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma

Pancreatic cancer is one of the most common causes of cancer-related deaths worldwide. The two major histological subtypes of pancreatic cancer are pancreatic ductal adenocarcinoma (PDAC), accounting for 90% o...

Authors: He-Li Gao, Wen-Quan Wang, Xian-Jun Yu and Liang Liu

The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017

Kidney cancer’s incidence and mortality vary in different regions and countries. To compare and interpret kidney cancer’s burden and change trends in the globe and in different countries, we conducted this stu...

Authors: Xianguang Bai, Ming Yi, Bing Dong, Xinhua Zheng and Kongming Wu

Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substa...

Authors: Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn and Ingolf Cascorbi

miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR

miR-100 is reported to be associated with cell proliferation and apoptosis. However, the function of miR-100 in mantle cell lymphoma (MCL) is unknown. The purpose of this study is to analyze the abnormal expre...

Authors: Luhui Lin, Yiqun Huang, Wei Zhuang, Ping Lin and Xudong Ma

Frontiers in the COVID-19 vaccines development

Novel corona virus caused pneumonia first reported in December, 2019 in Wuhan, China was later named COVID-19. Due to its special pathogenicity, COVID-19 transmitted with high speed beyond borders and has sign...

Authors: Ehtisham Ul Haq, Jifeng Yu and Jiancheng Guo

Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer

Pancreatic cancer continues to be one of the most aggressive malignant tumors. Work in recent years in cancer molecular biology has revealed that metabolic reprogramming is an additional hallmark of cancer tha...

Authors: Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo and Shunrong Ji

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells

Successful prevention of post-transplantation relapse after donor lymphocyte infusion (DLI) depends on its capability to mediate an effective graft-versus-leukemia (GVL) response while minimizing DLI-related t...

Authors: Yong-Rim Kwon, Hye Joung Kim, Min-Jung Sohn, Ji-Young Lim, Kyung-Shin Park, Seok Lee, Nack-Gyun Chung, Dae-Chul Jeong, Chang-Ki Min and Yoo-Jin Kim

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.

Authors: José Luis Piñana, Rodrigo Martino, Irene García-García, Rocío Parody, María Dolores Morales, Gonzalo Benzo, Irene Gómez-Catalan, Rosa Coll, Ignacio De La Fuente, Alejandro Luna, Beatriz Merchán, Anabelle Chinea, Dunia de Miguel, Ana Serrano, Carmen Pérez, Carola Diaz…

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study

Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an ...

Authors: Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi and Giovan Battista Ruffo

Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study

To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses.

Authors: Il Seok Daniel Jeong, Huan Mo, Anthony Nguyen, Esther G. Chong, Hsin Hsiang Clarence Tsai, Justin Moyers, Matthew Kim, Curtis Lacy, Vivek Shah, Eric Lau, Yi Xu and Huynh Cao

Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) se...

Authors: Pei Pei Che, Alessandro Gregori, Omidreza Firuzi, Max Dahele, Peter Sminia, Godefridus J. Peters and Elisa Giovannetti

The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China

PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may diffe...

Authors: Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng and Henghui Zhang

SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients

Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease, which lacks well-established diagnostic laboratory parameters that could be used to evaluate disease severity, thromboembolism or cardio...

Authors: Changqian Bao, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian

Macrophage, the potential key mediator in CAR-T related CRS

Chimeric antigen receptor (CAR) T cell therapy is a new frontier in cancer therapy. The toxicity of cytokine release syndrome (CRS) has become one of the major challenges that limits the wider use of CAR T cel...

Authors: Zhaonian Hao, Ruyuan Li, Li Meng, Zhiqiang Han and Zhenya Hong

Leukemia incidence trends at the global, regional, and national level between 1990 and 2017

Leukemias are a group of life-threatening malignant disorders of the blood and bone marrow. The incidence of leukemia varies by pathological types and among different populations.

Authors: Ying Dong, Oumin Shi, Quanxiang Zeng, Xiaoqin Lu, Wei Wang, Yong Li and Qi Wang

RDGN-based predictive model for the prognosis of breast cancer

Breast cancer is the most diagnosed malignancy in females in the United States. The members of retinal determination gene network (RDGN) including DACH, EYA, as well as SIX families participate in the prolifer...

Authors: Bing Dong, Ming Yi, Suxia Luo, Anping Li and Kongming Wu

Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation

Human prostate cancer spheres endowed with stem cell properties have been obtained from androgen-dependent cell line LNCaP after exposure to an epigenomic modulator phenethyl isothiocynate (PEITC). Sphere cell...

Authors: Jingjing Wu, Shundong Cang, Christina Liu, Whitman Ochiai and Jen Wei Chiao

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes

T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR T cell ...

Authors: Liqing Kang, Xiaowen Tang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Haiping Dai, Jia Chen, Guoqing Lin, Depei Wu and Lei Yu

Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma

Immune cell infiltration in the tumor microenvironment (TME) affects tumor initiation, patients’ prognosis and immunotherapy strategies. However, their roles and interactions with genomics and molecular proces...

Authors: Furong Liu, Lu Qin, Zhibin Liao, Jia Song, Chaoyi Yuan, Yachong Liu, Yu Wang, Heze Xu, Qiaofeng Zhang, Youliang Pei, Hongwei Zhang, Yonglong Pan, Xiaoping Chen, Zhanguo Zhang, Wanguang Zhang and Bixiang Zhang

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma c...

Authors: Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen and Tue Wenzel Kragstrup

Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma

Multiple myeloma is an incurable hematological malignancy characterized by a heterogeneous genetic and epigenetic landscape. Although a number of genetic aberrations associated with myeloma pathogenesis, progr...

Authors: Xi Yun Zhang, Deepa Rajagopalan, Tae-Hoon Chung, Lissa Hooi, Tan Boon Toh, Johann Shane Tian, Masturah Bte Mohd Abdul Rashid, Noor Rashidha Bte Meera Sahib, Mengjie Gu, Jhin Jieh Lim, Wilson Wang, Wee Joo Chng, Sudhakar Jha and Edward Kai-Hua Chow

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor contro...

Authors: Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock and Gerald Falchook

Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX in autoimmune hemolytic anemia (AIHA) and microangiopathic he...

Authors: Shih-Hsuan Chao, Yuh-Lih Chang, Jiin-Cherng Yen, Hsien-Tzung Liao, Tsai-Hung Wu, Chia-Li Yu, Chang-Youh Tsai and Yueh-Ching Chou

Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial

The high-risk refractory and/or relapsed (R/R) childhood acute leukemia prognosis is poor, and allogeneic stem cell transplantation (allo-HSCT) is the most prudent treatment modality. However, there are limite...

Authors: Binglei Zhang, Jian Zhou, Fengkuan Yu, Tianxin Lv, Baijun Fang, Dandan Fan, Zhenyu Ji and Yongping Song

Clinical implications of recurrent gene mutations in acute myeloid leukemia

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients’ individual variability, and recurrent gene mutations ar...

Authors: Jifeng Yu, Yingmei Li, Danfeng Zhang, Dingming Wan and Zhongxing Jiang

Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis

The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carr...

Authors: Bingbing Wen, Weiwen You, Sitian Yang and Xin Du

Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia

In this study, we retrospectively summarized the differences of molecular gene mutations between MDS and AML patients, as well as the young and older age groups of MDS and AML patients. We also analyzed the re...

Authors: Jifeng Yu, Yingmei Li, Tao Li, Yafei Li, Haizhou Xing, Hui Sun, Ling Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie and Zhongxing Jiang

The SMAC mimetic LCL-161 selectively targets JAK2^V617F mutant cells

Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs). Second mitochondria-derived activator of caspases (SM...

Authors: Brianna M. Craver, Thanh Kim Nguyen, Jenny Nguyen, Hellen Nguyen, Christy Huynh, Sarah J. Morse and Angela G. Fleischman

Immune pressures drive the promoter hypermethylation of neoantigen genes

Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immun...

Authors: Ming Yi, Bing Dong, Qian Chu and Kongming Wu

Gut microbiome and CAR-T therapy

Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly bein...

Authors: Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman and Parameswaran N. Hari

A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma

Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...

Authors: Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen and Yong Li

Advances and perspectives of PARP inhibitors

DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...

Authors: Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu and Suxia Luo

Recent advances on blinatumomab for acute lymphoblastic leukemia

Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine k...

Authors: Juanjuan Zhao, Yongping Song and Delong Liu

Development of molecular and pharmacological switches for chimeric antigen receptor T cells

The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality c...

Authors: Bill X. Wu, No-Joon Song, Brian P. Riesenberg and Zihai Li

The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...

Authors: Kongju Wu, Ming Yi, Shuang Qin, Qian Chu, Xinhua Zheng and Kongming Wu

Targeted and novel therapy in advanced gastric cancer

The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of a...

Authors: Julie H. Selim, Shagufta Shaheen, Wei-Chun Sheu and Chung-Tsen Hsueh

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L79...

Authors: Stephen R. Fairclough, Lesli A. Kiedrowski, Jessica J. Lin, Ori Zelichov, Gabi Tarcic, Thomas E. Stinchcombe, Justin I. Odegaard, Richard B. Lanman, Alice T. Shaw and Rebecca J. Nagy